ANIK — Anika Therapeutics, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 898437 ·
Last close
$14.89
Market Cap
$198.12M
52W High
$16.24
52W Low
$11.92
ADV30
110,540
Next earnings
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 29,612,000 18,997,000 -5,488,000 -5,056,000 179,387,000 41,020,000 45,486,000
Dec 2025 30,615,000 19,179,000 646,000 292,000 190,270,000 57,481,000 46,805,000
Sep 2025 27,817,000 15,584,000 -3,233,000 -2,329,000 189,437,000 57,990,000 42,632,000
Jun 2025 28,219,000 14,363,000 -4,180,000 -3,970,000 187,682,000 53,167,000 40,010,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$6,472,000
Investing CF
$-3,312,000
Financing CF
$-15,460,000
CapEx
$-5,433,000
Dividends Paid
Buybacks
$-14,204,000
EPS Diluted TTM
$-0.79
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$55,731,000
Inventory
$22,838,000
Receivables
$25,768,000
ST Investments
EBIT TTM
$-12,255,000
Pretax Income TTM
$-10,259,000
Interest Exp TTM
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$116,263,000
EBITDA
$-6,860,000
Free Cash Flow
$6,358,625
Enterprise Value
$182,703,680
Total Cash
$41,020,000
Total Debt
$25,736,000
Shares Out
13,305,624
Trailing EPS
$-0.79
Book Value
$10.03
ROE
-7.8%
ROA
-4.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 112,819,000 -11,051,000 -10,880,000 190,270,000 46,805,000 11,188,000
Dec 2024 119,907,000 -5,101,000 -56,385,000 202,740,000 48,751,000 5,403,000
Dec 2023 120,792,000 844,000 -82,667,000 270,632,000 58,367,000 -1,788,000
Dec 2022 113,827,000 3,670,000 -14,859,000 349,128,000 63,565,000 4,409,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.46

Peers — same industry

TickerNameMarket CapLastDaily %
TLSI TriSalus Life Sciences, Inc. $197.76M $3.22
EMBC Embecta Corp. $196.97M $3.32
KRMD KORU Medical Systems, Inc. $192.92M $4.20
INFU InfuSystem Holdings, Inc $191.93M $9.51
STXS Stereotaxis, Inc. $190.59M $1.95

News headlines (Yahoo Finance, 1h cache)

President of Anika Therapeutics Picks Up 51% More Stock
2026-05-03 13:36 · Yahoo
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter
2026-04-30 20:43 · Yahoo
Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary
2026-04-29 16:50 · Yahoo
Anika Therapeutics Q1 Earnings Call Highlights
2026-04-29 14:20 · Yahoo
Anika Reports First Quarter 2026 Financial Results
2026-04-29 11:05 · Yahoo
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
2026-04-16 11:30 · Yahoo
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
2026-04-15 20:01 · Yahoo
Telix Strengthens Board with Additional Director Appointments
2026-04-08 22:44 · Yahoo
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
2026-04-07 19:35 · Yahoo
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-03 21:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.